Erbitux and Lovenox drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Erbitux (cetuximab) and Lovenox (enoxaparin sodium). Common drug interactions include malignant neoplasm progression among females and arthralgia among males.

The phase IV clinical study analyzes what interactions people have when they take Erbitux and Lovenox. It is created by eHealthMe based on reports of 92 people who take the same drugs from the FDA, and is updated regularly.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

What is Lovenox?

Lovenox has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 48,149 Lovenox users. Check the latest studies of Lovenox.



On Jul, 11, 2026

92 people who take Erbitux and Lovenox together, and have interactions are studied.

Erbitux and Lovenox drug interactions.

What are the common drug interactions of Erbitux and Lovenox, by gender? *:

female:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Confusional state
  3. Butterfly rash
  4. Dehydration (dryness resulting from the removal of water)
  5. Depression
  6. Diarrhoea
  7. Disease progression
  8. Enterococcal infection
  9. Flat affect (absence of emotional response to a situation)
  10. Gliosis (a process leading to scars in the central nervous system)

male:

  1. Arthralgia (joint pain)
  2. Headache (pain in head)
  3. Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
  4. Enteritis infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus)
  5. Fall
  6. Stomatitis (inflammation of mucous membrane of mouth)
  7. Cough
  8. Diarrhoea
  9. Hypotension (abnormally low blood pressure)
  10. Nasopharyngitis (inflammation of the nasopharynx)

What are the common drug interactions of Erbitux and Lovenox, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Pain
  2. Rash

40-49:

  1. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  2. Hypotension (abnormally low blood pressure)
  3. Malignant neoplasm progression (cancer tumour came back)
  4. Loss of consciousness
  5. Acute sinusitis
  6. Arthralgia (joint pain)
  7. Asthenia (weakness)
  8. Bacteraemia (presence of bacteria in the blood)
  9. Catheter site infection (infection at the site of insertion)
  10. Chills (felling of cold)

50-59:

  1. Anaemia (lack of blood)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Butterfly rash
  4. Depression
  5. Dysphasia (language disorder marked by deficiency in the generation of speech)
  6. Enterococcal bacteraemia (presence of bacteria lactic acid in the blood)
  7. Enterococcal infection
  8. Feeding tube complication
  9. Flat affect (absence of emotional response to a situation)
  10. Gliosis (a process leading to scars in the central nervous system)

60+:

  1. Headache (pain in head)
  2. Arthralgia (joint pain)
  3. Dehydration (dryness resulting from the removal of water)
  4. Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
  5. Enteritis infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus)
  6. Fall
  7. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
  8. Stomatitis (inflammation of mucous membrane of mouth)
  9. Cough
  10. Nasopharyngitis (inflammation of the nasopharynx)

What are the existing conditions these people have? *

  1. Tonsil Cancer: 21 people, 22.83%
  2. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 20 people, 21.74%
  3. Colon Cancer: 16 people, 17.39%
  4. Pain: 10 people, 10.87%
  5. Nausea (feeling of having an urge to vomit): 10 people, 10.87%
  6. Lung Cancer - Non-Small Cell (lung cancer): 7 people, 7.61%
  7. Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 6 people, 6.52%
  8. Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 6 people, 6.52%

* Approximation only. Some reports may have incomplete information.

Do you take Erbitux and Lovenox?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Erbitux and Lovenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Erbitux:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lovenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Erbitux and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lovenox and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on cetuximab and enoxaparin sodium (the active ingredients of Erbitux and Lovenox, respectively), and Erbitux and Lovenox (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: